XCNQ
DOSE
Market cap9mUSD
Oct 08, Last price
0.10CAD
1D
11.11%
1Q
-16.67%
IPO
-87.50%
Name
Rapid Dose Therapeutics Corp
Chart & performance
P/E
—
P/S
4.87
EPS
—
Div yield, %
—
Shrs. gr., 5y
11.32%
Rev. gr., 5y
29.71%
Revenues
3m
+33.00%
Net income
-3m
L-37.28%
CFO
-270k
L-76.42%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Rapid Dose Therapeutics Corp., a life sciences enterprise based in Burlington, Canada, specializes in cutting-edge drug delivery systems aimed at enhancing health and well-being for individuals across Canada. Their core offering is the QuickStrip/PharmaStrip, an innovative oral, fast-dissolving film designed to swiftly introduce active compounds—such as pharmaceuticals, emulsified oils, and over-the-counter remedies—directly into the bloodstream. The product line includes targeted solutions like QuickStrip energy, infused with caffeine; QuickStrip B12, providing vitamin B12; and QuickStrip sleep, which delivers melatonin. Furthermore, the company provides bespoke services encompassing product innovation, manufacturing, and strategic consultation to the nutraceutical, cannabis healthcare, and pharmaceutical manufacturing sectors. Rapid Dose Therapeutics also maintains a significant research partnership with McMaster University, jointly developing advanced biopolymer compositions for optimized thin-film drug delivery and pioneering an orally administered COVID-19 vaccine candidate.
Key people
Mark Upsdell
President, Chief Executive Officer, Director · since 2017
Doug Hyland
Interim Chief Financial Officer · since 2020
Jason Lewis
Senior Vice President - Business Development, Director · since 2024
Director · since 2024
Marisa Cornacchia
Independent Director · since 2023
Peter Hasler
Independent Director · since 2020
Independent Director · since 2023
Angela O'Leary
Independent Director · since 2024
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2026‑02 | 2025‑02 | 2024‑02 | 2023‑02 | 2022‑02 | 2021‑02 | 2020‑02 | 2019‑02 | 2017‑09 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||